Registration Number
0223U002393,
0121U110083
, R & D reports
Title
Optimize the diagnosis and treatment of patients with non-Hodgkin's lymphoma of T-cell origin.
popup.stage_title
Head
Kriachok Iryna A.,
Registration Date
16-02-2023
Organization
National Cancer Institute
popup.description2
The object of research is non-Hodgkin's lymphomas, immunohistochemical and molecular genetic factors of the course of the disease. The purpose of the work is to improve the results of treatment of patients with lymphomas of T-cell origin by developing individualized approaches to therapy. Research methods and equipment: morphological, immunohistochemical and statistical. The All-Ukrainian Register of Lymphoma Data was created on the basis of the National Cancer Institute. 756 patients with a newly diagnosed lymphoma were included, of which 32 cases were T-cell lymphomas, which is 4.23%. The data of 98 patients with primary TCL were analyzed. Patients were divided into 4 groups depending on the type of TKL: 1st group (A) – leukemic forms (n=18); 2nd group (B) - nodal T-cell lymphomas (n = 58); 3rd group (C) - cutaneous T-cell lymphomas (n=15), 4th group (D) - extranodal T-cell lymphomas (n=7). All patients received treatment depending on the type of T-cell lymphoma: SMILE or HyperCVAD with/without auto-/allo-HSCT for the first group, CHOP-like regimens for the second group, and PUVA therapy, interferon and methotrexate for the third. Results: The overall response to therapy was 59.18% (n=58), due to complete and partial responses. The 18-month recurrence-free survival rate was 49%. 18-month overall survival was 63.8%. According to the statistical analysis, it was found that the 18-month recurrence-free survival for group B was higher compared to groups A, C, and D (72.36%, 24.93%, 38.75%, and 27.77%, respectively). Two-year overall survival for group B was also higher compared to other groups A, C, and D (74.81%, 27.32%, 47.23%, and 30.0%, respectively). Bone marrow involvement (p = 0.03) and Ki-67 expression > 65% (p = 0.006) were factors of unfavorable prognosis for patients. A database of patients with lymphoproliferative diseases who contracted COVID-19 has been created. The results of treatment of 126 patients were analyzed. Mortality among patients was 19.4%.
Product Description
popup.authors
Aleksyk Olena M.
Titorenko Iryna B.
Shypko Andrii F.
popup.nrat_date
2023-02-16
